Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Teladoc Health operates the largest global virtual care platform, delivering telehealth services across 175+ countries with ~90 million paid members in the US. The company combines direct-to-consumer telemedicine (general medical, mental health via BetterHelp) with B2B enterprise contracts serving employers, health plans, and hospital systems. The stock has collapsed 70% over the past year as the company faces structural margin pressure from post-pandemic demand normalization, intense competition in mental health services, and a challenged balance sheet requiring operational restructuring.
Teladoc generates revenue through two primary models: (1) B2B subscription contracts where employers/health plans pay PMPM fees ($2-8 per member) regardless of utilization, creating predictable recurring revenue but requiring scale to offset fixed platform costs, and (2) direct consumer subscriptions for BetterHelp ($260-320 per month) with high gross margins (70%+) but significant customer acquisition costs ($300-500 per subscriber). Competitive advantage historically centered on network effects from 90M+ member base and integrated platform spanning primary care, specialty, and mental health, but pricing power has eroded as competitors (Amwell, MDLive, health system-owned platforms) commoditize basic telemedicine. The company faces structural margin pressure as BetterHelp growth has decelerated sharply (consumer discretionary spending weakness) while enterprise contracts require continuous investment in clinical networks and technology without corresponding pricing increases.
BetterHelp subscriber trends and revenue per subscriber - mental health segment drives 30% of revenue and has experienced sharp deceleration from 2021 peak, with consumer discretionary spending and competitive intensity determining growth trajectory
Integrated Care membership growth and PMPM pricing - enterprise contract wins/losses with major employers and health plans, particularly retention rates during annual renewal cycles (typically 90%+ historically)
Path to profitability and cash flow generation - market focused on timeline to sustained positive EBITDA and ability to reduce $1.9B debt burden without equity dilution
Regulatory developments in telehealth reimbursement - CMS and state-level policies on virtual care parity with in-person visits, particularly for mental health and chronic disease management
Commoditization of basic telemedicine services as health systems (Kaiser, Intermountain, Cleveland Clinic) build proprietary virtual care platforms, reducing Teladoc's differentiation and pricing power in core Access segment
Regulatory uncertainty around telehealth reimbursement post-pandemic emergency waivers - potential rollback of interstate licensure flexibility or reduced Medicare/Medicaid payment parity could increase operating costs and limit addressable market
Secular shift toward value-based care models where at-risk providers (ACOs, Medicare Advantage plans) internalize virtual care rather than contracting with third-party platforms, disintermediating Teladoc's B2B model
Intense competition in mental health from venture-backed startups (Talkspace, Cerebral) and traditional providers (Optum Behavioral Health) offering comparable services at lower price points, pressuring BetterHelp's 30% revenue contribution
Amazon's entry into primary care telehealth through One Medical acquisition and Clinic platform creates well-capitalized competitor with distribution advantages through Prime membership base and employer relationships
Payer-owned platforms (UnitedHealth's Optum Virtual Care, Cigna's MDLIVE acquisition) vertically integrate telehealth, reducing third-party vendor spend and threatening Teladoc's largest customer segment
Elevated debt burden of $1.9B (0.75x debt/equity) with negative EBITDA creates refinancing risk if operating performance doesn't improve before 2027-2028 maturities, potentially forcing dilutive equity raise at depressed $0.7B market cap
Goodwill and intangible assets represent majority of $4.0B total assets following Livongo acquisition, with material impairment risk if revenue decline continues - prior $13.7B impairment in 2022 demonstrates valuation sensitivity
Negative working capital trends and $0.2B free cash flow provides minimal cushion for operational misses, with current ratio of 2.7x masking burn rate concerns if BetterHelp deterioration accelerates
moderate-to-high - BetterHelp (30% of revenue) is highly sensitive to consumer discretionary spending as out-of-pocket therapy subscriptions compete with other household expenses during economic weakness. Enterprise contracts show moderate cyclicality as employers reduce healthcare benefits or negotiate pricing during recessions, though telehealth adoption provides some defensive characteristics. Unemployment directly impacts covered lives as most members access Teladoc through employer-sponsored health plans. The company's negative correlation with in-person healthcare utilization provides partial offset during economic expansions when consumers resume traditional care.
Rising interest rates negatively impact Teladoc through multiple channels: (1) $1.9B debt burden carries floating-rate exposure, increasing interest expense and pressuring path to profitability, (2) higher discount rates compress valuation multiples for unprofitable growth companies, particularly severe for stocks trading at 0.3x sales, and (3) reduced consumer credit availability decreases BetterHelp subscription affordability. The company's negative free cash flow position makes refinancing risk material if rates remain elevated through 2027-2028 debt maturities.
Moderate credit exposure through enterprise customer concentration - top 10 clients represent estimated 25-30% of revenue, and health plan/employer financial stress could trigger contract non-renewals or pricing pressure. The company's own credit profile is stressed with 0.75x debt/equity and negative EBITDA, limiting access to growth capital and requiring operational cash flow improvement to avoid covenant violations or dilutive refinancing.
Distressed value/turnaround investors given 70% drawdown and 0.3x sales valuation, betting on operational restructuring and return to growth. The 24% FCF yield attracts contrarian value investors, though negative operating margins deter quality-focused funds. High volatility and binary outcome profile (successful turnaround vs bankruptcy/acquisition) appeals to event-driven hedge funds rather than long-term growth or income investors. Retail investor base has largely capitulated following collapse from $300+ peak to current levels.
high - Stock exhibits 2.0+ beta to broader market with extreme sensitivity to quarterly earnings misses, telehealth sector sentiment, and interest rate volatility. The $0.7B market cap and distressed valuation create outsized moves on operational updates, with 30-50% single-day swings common following earnings releases. Illiquidity in German listing (4LL.F) versus US primary listing (TDOC) amplifies volatility.